PMID- 24782287
OWN - NLM
STAT- MEDLINE
DCOM- 20160504
LR  - 20150806
IS  - 2194-9387 (Electronic)
IS  - 2194-9379 (Linking)
VI  - 65
IP  - 8
DP  - 2015 Aug
TI  - Effect of Chronic Administration of Buspirone and Fluoxetine on Inflammatory 
      Cytokines in 6-Hydroxydopamine-lesioned Rats.
PG  - 393-7
LID - 10.1055/s-0034-1374615 [doi]
AB  - Neuro-inflammation in Parkinson's disease (PD) is associated with glial cell 
      activation and production of different inflammatory cytokines. In this study we 
      investigated the effect of chronic administration of buspirone and fluoxetine on 
      cerebrospinal fluid (CSF) levels of inflammatory cytokines, TNF-alpha, IL-1beta and IL-6 
      in 6-hydroxydopamine (6-OHDA)-lesioned rats.6-OHDA (8 mug/2 mul/rat) was injected 
      unilaterally into the central region of the substantia nigra pars copmacta (SNc) 
      and after 21 days lesioned rats were treated with buspirone and fluoxetine 
      intraperitonealy (i.p.) for 10 days. CSF samples were collected at tenth day of 
      drugs administration and were analysed by ELISA method to measure TNF-alpha, IL-1beta 
      and IL-6 levels.The results showed that the CSF levels of TNF-alpha was increased 3 
      weeks after 6-OHDA injection while there was a significant decrease in TNF-alpha 
      levels of parkinsonian animals treated with buspirone (1 mg/kg) and fluoxetine (1 
      mg/kg). IL-1beta and IL-6 both were decreased in parkinsonian rats, while their 
      level was increased in buspirone (1 mg/kg) and fluoxetine (1 mg/kg) treated 
      parkinsonian rats.Our study indicates that chronic administration of buspirone 
      and fluoxetine in 6-OHDA-lesioned rats restores central concentration of 
      inflammatory cytokines to the basal levels. We suggest that serotonergic agents 
      can be used as adjuvant therapy along with commonly used anti-parkinsonian drugs 
      by modulation of cerebral inflammatory cytokines. We suggest that the further 
      clinical investigations may be carried out to prove this hypothesis.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Sharifi, H
AU  - Sharifi H
AD  - Department of Pharmacology, Faculty of Pharmacy, Urmia University of Medical 
      Science,Urmia, Iran.
FAU - Nayebi, A M
AU  - Nayebi AM
AD  - Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, 
      Iran.
FAU - Farajnia, S
AU  - Farajnia S
AD  - Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, 
      Iran.
FAU - Haddadi, R
AU  - Haddadi R
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tabriz University 
      of Medical Sciences, Tabriz, Iran.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140429
PL  - Germany
TA  - Drug Res (Stuttg)
JT  - Drug research
JID - 101602406
RN  - 0 (Interleukin-1beta)
RN  - 0 (Interleukin-6)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 01K63SUP8D (Fluoxetine)
RN  - 8HW4YBZ748 (Oxidopamine)
RN  - TK65WKS8HL (Buspirone)
SB  - IM
MH  - Animals
MH  - Buspirone/*administration & dosage
MH  - Cerebrospinal Fluid/metabolism
MH  - Fluoxetine/*administration & dosage
MH  - Interleukin-1beta/*metabolism
MH  - Interleukin-6/*metabolism
MH  - Male
MH  - Oxidopamine/*administration & dosage
MH  - Parkinson Disease/drug therapy/metabolism
MH  - Parkinsonian Disorders/drug therapy/metabolism
MH  - Rats
MH  - Rats, Wistar
MH  - Substantia Nigra/drug effects/metabolism
MH  - Tumor Necrosis Factor-alpha/*metabolism
EDAT- 2014/05/02 06:00
MHDA- 2016/05/05 06:00
CRDT- 2014/05/01 06:00
PHST- 2014/05/01 06:00 [entrez]
PHST- 2014/05/02 06:00 [pubmed]
PHST- 2016/05/05 06:00 [medline]
AID - 10.1055/s-0034-1374615 [doi]
PST - ppublish
SO  - Drug Res (Stuttg). 2015 Aug;65(8):393-7. doi: 10.1055/s-0034-1374615. Epub 2014 
      Apr 29.